Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 5/2006

01-11-2006 | Original Article

A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors

Authors: A. Felici, W. J. Loos, J. Verweij, I. Cirillo, P. de Bruijn, K. Nooter, R. H. J. Mathijssen, M. J. A. de Jonge

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2006

Login to get access

Abstract

Background: The purpose of this study was to look at the pharmacokinetics of docetaxel, cisplatin-derived platinum and 5-fluorouracil (5-FU), when used in combination, to exclude potential clinically relevant pharmacokinetic interactions. Methods: Fifteen patients with recurrent or metastatic solid tumors were randomized to receive docetaxel 75 mg/m2 and cisplatin 75 mg/m2 in the first treatment course on day 1 and the same combination plus 5-FU 750 mg/m2/day on days 1–5 in the second course, or the two treatment courses in reversed order. Cycles were repeated every 3 weeks. A pharmacokinetic analysis was performed during the first two cycles. Results: Full pharmacokinetic data was available for 12 of the 15 patients. Treatment was tolerated well, with frequency of toxicity consistent with the safety profile known for docetaxel, cisplatin and 5-FU. Mean clearance values for docetaxel and cisplatin showed no statistically significant difference across the “triple” and the “double” combination treatments, and the mean pharmacokinetic parameters of all agents were within the ranges for previously reported single agent treatment. Conclusion: No clinically relevant pharmacokinetic interactions between docetaxel, cisplatin and 5-FU used in combination were noticed in this study.
Literature
1.
Colevas AD, Busse PM, Norris CM et al (1998) Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. J Clin Oncol 16:1331–1339PubMed
2.
Colevas AD, Norris CM, Tisheler RB et al (1999) Phase II of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol 17:3503–3511PubMed
3.
Posner MR, Glisson B, Frenette G et al (2001) Multicenter phase I–II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 19:1096–1104PubMed
4.
Janinis J, Papadakou M, Panagos G et al (2001) Sequential chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer. Am J Clin Oncol 24:227–231PubMedCrossRef
5.
Haddad R, Tishler RB, Norris CM et al (2003) Docetaxel, cisplatin, 5-fluorouracil (tpf)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment. Oncologist 8:35–44PubMedCrossRef
6.
Schrijvers D, Van Herpen C, Kerger J et al (2004) Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I–II feasibility study. Ann Oncol 15:638–645PubMedCrossRef
7.
Roth AD, Maibach R, Fazio N et al (2004) 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I–II trial. Ann Oncol 15:759–764PubMedCrossRef
8.
Ringel I, Horowitz S (1991) Studies with RP 56976 (Taxotere): a semisynthetic analog of taxol. J Natl Cancer Inst 83:288–291PubMedCrossRef
9.
10.
Urien S, Barrè J, Morin C (1996) Docetaxel serum protein binding with high affinity to alpha1-acid glycoprotein. Invest New Drugs 14:1547–1551CrossRef
11.
Schellens JHM, Ma J, Planting ASTh et al (1996) Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer 74:323–326PubMed
12.
Leichman CG, Fleming TR, Muggia F et al (1995) Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group Study. J Clin Oncol 13:1303–1311PubMed
13.
Pronk LC, Schellens JHM, Planting ASTh et al (1997) Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. J Clin Oncol 15:1071–1079PubMed
14.
Van Den Neste E, de Valeriola D, Kerger J et al (2000) A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors. Clin Cancer Res 6:64–71
15.
Ando M, Watanabe T, Sasaki Y et al (1998) A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer. Br J Cancer 77:1937–1943PubMed
16.
Loos WJ, Verweij J, Nooter K et al (1997) Sensitive determination of docetaxel in human plasma by liquid–liquid extraction and reverse-phase high-performance liquid chromatography. J Chromatogr B 963:437–441
17.
Ma J, Verweij J, Planting AST et al (1995) Current sample handling methods for measurement of platinum–DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair. Br J Cancer 71:512–517PubMed
18.
Loos WJ, de Bruijn P, van Zuylen L et al (1999) Determination of 5-fluorouracil in microvolumes of human plasma by solvent extraction and high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 735:293–297PubMedCrossRef
19.
Launay-Iliadis MC, Bruno R, Cosson V et al (1995) Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modelling and nonparametric maximum-likelihood estimation. Cancer Chemother Pharmacol 37:47–54PubMedCrossRef
20.
Casale F, Canapro R, Serpe L et al (2004): Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. Pharmacol Res 50:173–179PubMedCrossRef
21.
Minami H, Ohe Y, Niho S et al (2004) Comparison of pharmacokinetics and pharmacodynamics of docetaxel and cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients? J Clin Oncol 22:2901–2908PubMedCrossRef
22.
Bruno R, Vivier N, Vergniol JC et al (1996) A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 24:153–172PubMedCrossRef
23.
Bruno R, Vivier N, Veyrat-Follet C, Montay G, Rhodes G (2001) Population pharmacokinetics and pharmacokinetic–pharmacodynamic relationships for docetaxel. Invest New Drugs 19:163–169PubMedCrossRef
24.
Bissery M, Vrignaud P, Lavelle F (1995) Preclinical profile of docetaxel (Taxotere): efficacy as single agent and in combination. Semin Oncol 22(Suppl 13):3–16
25.
Ajani JA, Fodor M, Van Cutsem E et al (2005) Multinational randomized phase II trial of docetaxel (T) and cisplatin (C) with or without 5-fluorouracil (FU) in patients (Pts) with advanced gastric or GE junction adenocarcinoma (AGC-AGEJC). J Clin Oncol 23:5660–5667PubMedCrossRef
26.
Ajani JA, Van Cutsem E, Moiseyenko V et al (2003) Docetaxel (D), cisplatin, 5-fluorouracil compared with cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naïve patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): interim results of a randomized phase III trials (V325). Proc Am Soc Clin Oncol A #999
27.
Roth AD, Maibach R, Falk S et al (2004) Docetaxel–cisplatin–5FU (TCF) versus docetaxel–cisplatin (TC) versus epirubicin–cisplatin–5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): a randomized phase II trial of the Swiss Group for Clinical Research (SAKK). Proc Am Soc Clin Oncol 22(14S):4020
28.
Yuki S, Komatsu Y, Machida N et al (2005) Phase I study of docetaxel, cisplatin and 5-fluorouracil (TPF) as first-line chemotherapy in patients with advanced esophageal cancer. Hokkaido Gastrointestinal Cancer Study Group (HGCSG) study. Proc Am Soc Clin Oncol 23:4181
29.
Scanlon KJ, Newman EM, Lu Y et al (1986) Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci 83:8923–8925PubMedCrossRef
30.
Scanlon KJ, Lu Y, Kashani-Sabet M et al (1988) Mechanisms for cisplatin-Fura synergism and cisplatin resistance in human ovarian carcinoma cells in vitro and in vivo. Adv Exp Med Biol 244:127–135PubMed
31.
Crul M, van Waardenburg RCAM, Beijnen JH, Schellens JHM (2002) DNA-based drug interactions of cisplatin. Cancer Treat Rev 28:291–303PubMedCrossRef
32.
Ma J, Verweij J, Planting AST et al (1996) Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes. Cancer Chemother Pharmacol 37:382–384PubMedCrossRef
33.
McLeod HL (1998) Clinically relevant drug–drug interaction in oncology. Br J Clin Pharmacol 45:539–544PubMedCrossRef
Metadata
Title
A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors
Authors
A. Felici
W. J. Loos
J. Verweij
I. Cirillo
P. de Bruijn
K. Nooter
R. H. J. Mathijssen
M. J. A. de Jonge
Publication date
01-11-2006
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2006
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-006-0221-x

Other articles of this Issue 5/2006

Cancer Chemotherapy and Pharmacology 5/2006 Go to the issue

Clinical Trial Report

A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group

Original Article

Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma

Short Communication

FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities

Original Article

Effect of CYP2D6 genetic polymorphism on the population pharmacokinetics of tipifarnib

Original Article

High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2

Original Article

Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits